Penumbra, Inc. Reports Impressive Financial Growth
Penumbra, Inc. (NYSE: PEN), renowned as a leading thrombectomy company, has announced remarkable financial results for the third quarter of 2025, showcasing impressive growth across various metrics.
Key Financial Highlights
In the third quarter of 2025, Penumbra generated a revenue of $354.7 million, marking an increase of 17.8% compared to the same quarter of 2024. This number translates to a 16.9% growth in constant currency. Dominating the market, the U.S. operations contributed $275.0 million to this figure, demonstrating a robust increase of 21.5% year-over-year.
U.S. Thrombectomy Revenue Surges
Within the U.S. market, thrombectomy revenue reached an impressive $192.0 million, reflecting an 18.5% growth from the previous year. The rise of revenue from the U.S. venous thromboembolism (VTE) segment was even more pronounced, displaying an astonishing 34% increase relative to the same period last year.
Operational and Profit Margin Insights
Penumbra recorded income from operations of $48.8 million, representing an operating margin of 13.8%. Additionally, the company reported a net income of $45.9 million and adjusted EBITDA of $66.7 million, which equates to a net income margin of 12.9% and an adjusted EBITDA margin of 18.8% for the quarter.
The gross profit for Q3 2025 was reported at $240.4 million, taking up 67.8% of total revenue, up from 66.5% in the same quarter of 2024. The enhanced gross margin can largely be attributed to optimized product and regional mix, improvements in productivity, and strategic production initiatives set to meet growing demands in the healthcare sector.
Operating expenses totaled $191.6 million, representing 54.0% of total revenue. This is a notable decrease from $164.9 million or 54.8% in Q3 2024. Penumbra has strategically optimized its R&D and SG&A expenditures to support its growth trajectory.
Financial Outlook for 2025
As a part of their commitment to transparency, Penumbra has revised its full-year revenue guidance, now anticipating total revenue growth for the year to be between $1.375 billion and $1.38 billion, translating to an expected growth of 15% to 16% over 2024's revenue of $1.195 billion. They also continue to project a strong U.S. thrombectomy growth rate of 20% to 21%.
Webcast and Conference Call
Penumbra will host a conference call at the close of markets to discuss these results in detail. Interested parties can access the call by dialing (888) 596-4144 or tune into the webcast available on the company's investor relations page.
About Penumbra
Penumbra, Inc. is at the forefront of innovation in thrombectomy, committed to developing groundbreaking technologies that address challenging medical conditions. Their extensive portfolio includes advanced devices aimed at effectively treating conditions like ischemic strokes and venous thromboembolism, promoting enhanced patient outcomes across over 100 countries worldwide.
Frequently Asked Questions
What are the main highlights of Penumbra's Q3 results?
Penumbra reported a 17.8% increase in revenue, totaling $354.7 million, with strong contributions from U.S. thrombectomy products.
How much growth did Penumbra experience in the U.S. market?
U.S. revenue increased by 21.5%, driven by a notable 18.5% growth in thrombectomy revenue.
What is Penumbra's outlook for 2025?
The company has raised its revenue guidance to a range of $1.375 billion to $1.38 billion, forecasting 15% to 16% growth compared to 2024.
How has the company's gross margin changed?
The gross margin improved to 67.8% for Q3 2025, up from 66.5% the previous year, due to favorable product mix and productivity improvements.
Where can investors find more information?
Investors can access detailed financial information and the webcast on Penumbra's website during their quarterly earnings conference call.
